Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Relationship between Health Costs and Inflammatory Profile in Public Health

Author(s): Ana P.R. Rocha, Fábio S. Lira*, Denise R. Bueno, Daniela S. Inoue, Dayane C. Queiroz and Jamile S. Codogno

Volume 25, Issue 43, 2019

Page: [4622 - 4629] Pages: 8

DOI: 10.2174/1381612825666191106155903

Price: $65

Abstract

Introduction: The association between obesity and physical activity level is well established in the literature, as well as its consequences that lead to chronic noncommunicable diseases. In addition, it is also possible to obtain the immunometabolic mechanism that explains the pathway of associations between obesity, chronic noncommunicable diseases and the level of physical activity. It also seems clear that treating illnesses has a financial impact on healthcare systems around the world, so it seems important to assess the financial impact on the healthcare system of individuals with immunometabolic dysfunction.

Aim: This study aimed to assess whether there is a correlation between metabolic and inflammatory markers and healthcare costs according to body adiposity and habitual physical activity (HPA).

Methods: This is a cross-sectional study, where the sample includes men and women aged over 50. Participants underwent evaluations that included the following variables: i) immunometabolic markers, ii) healthcare costs, iii) obesity, iv) habitual physical activity, and v) history of personal illness. Statistical significance was set at values lower than 5% and the software used was BioEstat.

Results: The correlation between metabolic and inflammatory markers and healthcare costs demonstrated a positive and significant relationship, adjusted for obesity and HPA, between glucose concentrations and exam costs (r = 0.343, p-value = 0.007) and total cost (r = 261; p-value = 0.043); HOMA index and cost of exams (r = 0.267; pvalue = 0.038); and IL-10 and cost of medical consultation (r = 0.297; p-value = 0.020).

Conclusion: Metabolic and inflammatory markers may be related to the costs of consultations and examinations, independent of obesity and HPA.

Keywords: Noncommunicable diseases, physical activities, obesity, healthcare cost, cytokines, healthcare system.

« Previous Next »
[1]
Noncommunicable diseases country profiles 2018 Geneva: World Health Organization 2018.Available at. https://www.who.int/nmh/publications/ncd-profiles-2018/en/
[2]
Primary attention and Health care networks, CONASS 2015.Available at. http://www.conass.org.br/biblioteca/pdf/A-Atencao-Primaria-e-as-Redes-de-Atencao-a-Saude.pdf
[3]
Cinkajzlová A, Mráz M, Haluzík M. Lymphocytes and macrophages in adipose tissue in obesity: markers or makers of subclinical inflammation? Protoplasma 2017; 254(3): 1219-32.
[http://dx.doi.org/10.1007/s00709-017-1082-3] [PMID: 28150048]
[4]
Chatzigeorgiou A, Karalis KP, Bornstein SR, Chavakis T. Lymphocytes in obesity-related adipose tissue inflammation. Diabetologia 2012; 55(10): 2583-92.
[http://dx.doi.org/10.1007/s00125-012-2607-0]
[5]
Grant RW, Dixit VD. Adipose tissue as an immunological organ. Obesity (Silver Spring). NIH Public Access 2015; 23(3): 512-8.
[http://dx.doi.org/10.1002/oby.21003]
[6]
Suzuki K. chronic inflammation as an immunological abnormality and effectiveness of exercise. Biomolecules 2019; 9(6): 223.
[http://dx.doi.org/10.3390/biom9060223] [PMID: 31181700]
[7]
Kiliaan AJ, Arnoldussen IAC, Gustafson DR. Adipokines: a link between obesity and dementia? Lancet Neurol NIH Public Access 2014; 13(9): 913-23.
[http://dx.doi.org/10.1016/S1474-4422(14)70085-7]
[8]
Lira FS, Rosa JC, Pimentel GD, et al. Endotoxin levels correlate positively with a sedentary lifestyle and negatively with highly trained subjects. Lipids Health Dis 2010; 9(1): 82.
[http://dx.doi.org/10.1186/1476-511X-9-82]
[9]
Pedersen BK. The diseasome of physical inactivity-and the role of myokines in muscle-fat cross talk. J Physiol 2009; 587(Pt. 23): 5559-68.
[http://dx.doi.org/10.1113/jphysiol.2009.179515] [PMID: 19752112]
[10]
Costa ESM, Hyeda A. Chronic case management: clinical governance with cost reductions. Rev Assoc Med Bras 2016; 62(3): 231-5.
[11]
Bielemann RM, da Silva BGC, Coll C de VN, Xavier MO, Silva SG. Burden of physical inactivity and hospitalization costs due to chronic diseases. Rev Saude Publica Universidade de São Paulo Faculdade de Saúde Pública 2015; 49.Available at. http://www.ncbi.nlm.nih.gov/pubmed/26487291
[http://dx.doi.org/10.1590/S0034-8910.2015049005650]
[12]
Valero-Elizondo J, Salami JA, Ogunmoroti O, et al. Favorable cardiovascular risk profile is associated with lower healthcare costs and resource utilization: the 2012 medical expenditure panel survey. Circ Cardiovasc Qual Outcomes 2016; 9(2): 143-53.
[13]
Oliveira ML, Santos LMP, da Silva EN. Direct healthcare cost of obesity in brazil: an application of the cost-of-illness method from the perspective of the public health system in 2011. PLoS One 2015; 10(4) e0121160
[14]
Elmer DJ, Laird RH, Barberio MD, Pascoe DD. Inflammatory, lipid, and body composition responses to interval training or moderate aerobic training. Eur J Appl Physiol 2016; 116(3): 601-9.
[http://dx.doi.org/10.1007/s00421-015-3308-4]
[15]
Codogno JS, Turi BC, Kemper HCG, Fernandes RA, Christofaro DGD, Monteiro HL. Physical inactivity of adults and 1-year health care expenditures in Brazil. Int J Public Health 2015; 60(3): 309-16.
[http://dx.doi.org/10.1007/s00038-015-0657-z] [PMID: 25680327]
[16]
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412-9.
[http://dx.doi.org/10.1007/BF00280883]
[17]
Codogno JS, Fernandes RA, Monteiro HL. Physical activity and healthcare cost of type 2 diabetic patients seen at basic units of healthcare. Arq Bras Endocrinol Metabol 2012; 56(1): 6-11.
[18]
Codogno JS. The burden of physical activity on type 2 diabetes public healthcare expenditures among adults: a retrospective study. BMC Public Health. BioMed Central Ltd 2011; 11(1): 275.
[19]
Codogno JS T BC, Fernandes RA, Monteiro HL. Comparison of expenditures related to primary health care in men and women from Bauru, São Paulo, Brazil 2010. Epidemiol Serv Saude 2015; 24(1): 363-80.
[http://dx.doi.org/10.5123/S1679-49742015000100013]
[20]
Coin conversion Available at. http://www4.bcb.gov.br/pec/conversao/conversao.asp
[21]
Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Champaign, IL: human kinetics books 1988.Available at. http://www.worldcat.org/title/anthropometric-standardization-reference-manual/oclc/15592588
[22]
Baecke J, Burema J, Frijters J, et al. The Questionnaire of Baecke for Measurement of a person’s habitual physical activity. Am J Clin Nutr 1982; 936-42.
[http://dx.doi.org/10.1093/ajcn/36.5.936] [PMID: 7137077]
[23]
Florindo AA, Maria E, Dias De Oliveira Latorre R. Methodology to evaluation the habitual physical activity in men aged 50 years or more. Rev Bras Med Esporte 2003; 9Available at. http://www.scielo.br/pdf/rbme/v9n3/17260.pdf
[24]
Brazilian Diabetes Society Guidelines 2017-2018. Brazilian Diabetes Society 2017.Available at. https://www.diabetes.org.br/profissionais/images/2017/diretrizes/diretrizes-sbd-2017-2018.pdf
[25]
Alpcon Insulina ELISA Available at. https://s3.amazonaws.com/alpco-docs/80/80-INSHU-E01.1,E10.1.pdf
[26]
Geloneze B, Vasques AC, Stabe CF, et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metabol 2009; 53(2): 281-7.
[http://dx.doi.org/10.1590/S0004-27302009000200020]
[27]
Faludi AA, Izar MCO, Saraiva JFK, et al. Atualização da diretriz brasileira de dislipidemias e prevenção da aterosclerose - 2017. Arq Bras Cardiol 2017; 109(2)(Suppl. 1): 1-76.
[http://dx.doi.org/10.5935/abc.20170121]
[28]
Bahia LR, Araujo DV, Schaan BD, et al. The costs of Type 2 Diabetes mellitus outpatient care in the brazilian public health system. Value Health 2011; 14(5): S137-40.
[29]
Domeikienė A, Vaivadaitė J, Ivanauskienė R, Padaiga Ž. Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania. Medicina (B Aires) 2014; 50(1): 54-60.
[http://dx.doi.org/10.1016/j.medici.2014.05.007]
[30]
American Diabetes Association AD. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. Amn Diabet Assoc 2013; 36(4): 1033-46.
[31]
Leung MYM, Carlsson NP, Colditz GA, Chang S-H. The burden of obesity on diabetes in the united states: medical expenditure panel survey, 2008 to 2012. Value Health Elsevier 2017; 20(1): 77-84.
[32]
Turi BC, Monteiro HL, Fernandes RA, Codogno JS. The impact of physical activity on mitigation of health care costs related to diabetes mellitus: findings from developed and developing settings. Curr Diabetes Rev 2016; 12(4): 307-11.
[http://dx.doi.org/10.2174/1573399812666151016103245] [PMID: 26472573]
[33]
Richter EA, Hargreaves M. Exercise, Glut4, and skeletal muscle glucose uptake Available at. https://www.physiology.org/doi/pdf/10.1152/physrev.00038.2012
[34]
Donnelly J, Blair S, Jakicic J, Manore M, Rankin J, Smith B. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sport Exerc 2009; 41(2): 459-71.
[http://dx.doi.org/10.1249/MSS.0b013e3181949333]
[35]
Elmer DJ, Laird RH, Barberio MD, Pascoe DD. Inflammatory, lipid, and body composition responses to interval training or moderate aerobic training. Eur J Appl Physiol 2016; 116(3): 601-9.
[http://dx.doi.org/10.1007/s00421-015-3308-4]
[36]
Cavusoglu E, Marmur JD, Hojjati MR, et al. Plasma Interleukin-10 levels and adverse outcomes in acute coronary syndrome. Am J Med 2011; 124(8): 724-30.
[http://dx.doi.org/10.1016/j.amjmed.2011.02.040]
[37]
Suyasa IK, Kawiyana IKS, Bakta IM, Widiana IGR. Interleukin-6 and ratio of plasma interleukin-6/interleukin-10 as risk factors of symptomatic lumbar osteoarthritis. World J Orth 2017; 8(2): 149-55.
[38]
Welsh P, Murray HM, Ford I, et al. Circulating Interleukin-10 and risk of cardiovascular events. Arterioscler Thromb Vasc Biol 2011; 31(10)
[http://dx.doi.org/10.1161/ATVBAHA.111.231795]
[39]
Yilmaz MI, Solak Y, Saglam M, et al. The relationship between IL-10 levels and cardiovascular events in patients with CKD. Clin J Am Soc Nephrol. Amn Soc Nephrol 2014; 9(7): 1207-16.
[40]
Azambuja MIR, Foppa M, Maranhão MF de C, Achutti AC. Economic burden of severe cardiovascular diseases in Brazil: an estimate based on secondary data. Arq Bras Cardiol 2008; 91(3): 163-71.
[41]
Ademi Z, Liew D, Zomer E, et al. Outcomes and excess costs among patients with cardiovascular disease. Heart Lung Circ 2013; 22(9): 724-30.
[http://dx.doi.org/10.1016/j.hlc.2013.02.002]
[42]
Mrosewski I, Jork N, Gorte K, et al. Regulation of osteoarthritis-associated key mediators by TNFα and IL-10: effects of IL-10 overexpression in human synovial fibroblasts and a synovial cell line. Cell Tissue Res 2014; 357(1): 207-23.
[43]
Li S, Wan J, Anderson W, et al. Downregulation of IL-10 secretion by Treg cells in osteoarthritis is associated with a reduction in Tim-3 expression. Biomed Pharmacother 2016; 79: 159-65.
[44]
Sharif B, Kopec JA, Wong H, Anis AH. Distribution and drivers of average direct cost of osteoarthritis in canada from 2003 to 2010. Arthritis Care Res (Hoboken) 2017; 69(2): 243-51.

Rights & Permissions Print Cite
Article Metrics
8
© 2024 Bentham Science Publishers | Privacy Policy